foselutoclax   Click here for help

GtoPdb Ligand ID: 13366

Synonyms: UBX-1325 | UBX1325
Compound class: Synthetic organic
Comment: Foselutoclax (UBX1325) is a small-molecule inhibitor of BCL-xL that has a senolytic action [2]. Pharmacological elimination of senescent cells is a mechanism that is under investigation to treat pathologies that are promoted in the presence of senescent cells. This senolytic strategy is considered to be an alternative to anti-vascular endothelial growth factor therapies such as aflibercept in degenerative edematous retinal conditions (e.g. diabetic retinopathy) [3].

foselutoclax is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 16
Hydrogen bond donors 5
Rotatable bonds 21
Topological polar surface area 261.23
Molecular weight 1159.69
XLogP 6.88
No. Lipinski's rules broken 4

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(C)N1C(=C(C(=C1C2=CC=C(C=C2)Cl)C3=CC=CC(=C3)N4CCN(CC4)C5=CC=C(C=C5)NS(=O)(=O)C6=CC=C(C(=C6)S(=O)(=O)C(F)(F)F)N[C@H](CCN7CCC(CC7)OP(=O)(O)O)CSC8=CC=CC=C8)C(=O)O)C
Isomeric SMILES CC1=C(C(=C(N1C(C)C)C2=CC=C(C=C2)Cl)C3=CC(=CC=C3)N4CCN(CC4)C5=CC=C(C=C5)NS(=O)(=O)C6=CC(=C(C=C6)N[C@H](CCN7CCC(CC7)OP(=O)(O)O)CSC8=CC=CC=C8)S(=O)(=O)C(F)(F)F)C(=O)O
InChI InChI=1S/C53H59ClF3N6O10PS3/c1-35(2)63-36(3)49(52(64)65)50(51(63)37-12-14-39(54)15-13-37)38-8-7-9-43(32-38)62-30-28-61(29-31-62)42-18-16-40(17-19-42)59-77(71,72)46-20-21-47(48(33-46)76(69,70)53(55,56)57)58-41(34-75-45-10-5-4-6-11-45)22-25-60-26-23-44(24-27-60)73-74(66,67)68/h4-21,32-33,35,41,44,58-59H,22-31,34H2,1-3H3,(H,64,65)(H2,66,67,68)/t41-/m1/s1
InChI Key FSZILRQCEAUYPL-VQJSHJPSSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. (1993)
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.
Cell, 74 (4): 597-608. [PMID:8358789]
2. Crespo-Garcia S, Fournier F, Diaz-Marin R, Klier S, Ragusa D, Masaki L, Cagnone G, Blot G, Hafiane I, Dejda A et al.. (2024)
Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results.
Nat Med, 30 (2): 443-454. [PMID:38321220]
3. Hassan JW, Bhatwadekar AD. (2022)
Senolytics in the treatment of diabetic retinopathy.
Front Pharmacol, 13: 896907. [PMID:36091769]
4. Kirkland JL, Tchkonia T. (2020)
Senolytic drugs: from discovery to translation.
J Intern Med, 288 (5): 518-536. [PMID:32686219]
5. Tsuruda P, Chaney s, Dejda A, Dasgupta S, Creespo-Garcia S, Rao S, Armstrong S, Marquess D, Sapieha P, Beltran P. 
UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy.
Accessed on 16/05/2024. Modified on 16/05/2024. iovs.arvojournals.org, https://iovs.arvojournals.org/article.aspx?articleid=2774856